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The American College of Cardiology (ACC) and the
American Heart Association (AHA) are committed to the
prevention and management of cardiovascular diseases
through professional education and research for clini-
cians, providers, and patients. Since 1980, the ACC andAHA have shared a responsibility to translate scientiﬁc
evidence into clinical practice guidelines (CPGs) with
recommendations to standardize and improve cardio-
vascular health. These CPGs, based on systematic
methods to evaluate and classify evidence, provide a
cornerstone of quality cardiovascular care.
In response to published reports from the Institute of
Medicine (1,2) and the ACC/AHA’s mandate to evaluate
new knowledge and maintain relevance at the point of
care, the ACC/AHA Task Force on Practice Guidelines
(Task Force) began modifying its methodology. This
modernization effort is published in the 2012 Methodol-
ogy Summit Report (3) and 2014 perspective article (4).
The latter recounts the history of the collaboration,
changes over time, current policies, and planned initia-
tives to meet the needs of an evolving healthcare envi-
ronment. Recommendations on value in proportion to
resource utilization will be incorporated as high-quality
comparative-effectiveness data become available (5).
The relationships between CPGs and data standards,
appropriate use criteria, and performance measures are
addressed elsewhere (4).
Intended Use—CPGs provide recommendations applicable
to patients with or at risk of developing cardiovascular
disease. The focus is on medical practice in the United
States, but CPGs developed in collaboration with other
organizations may have a broader target. Although CPGs
may be used to inform regulatory or payer decisions, the
intent is to improve the quality of care and be aligned
with the patient’s best interest.
Evidence Review—Guideline writing committee (GWC)
members are charged with reviewing the literature;
weighing the strength and quality of evidence for or
against particular tests, treatments, or procedures; and
estimating expected health outcomes when data exist. In
analyzing the data and developing CPGs, the GWC uses
evidence-based methodologies developed by the Task
Force (6). A key component of the ACC/AHA CPG meth-
odology is the development of recommendations on the
basis of all available evidence. Literature searches focus
on randomized controlled trials (RCTs) but also include
registries, nonrandomized comparative and descriptive
studies, case series, cohort studies, systematic reviews,
and expert opinion. Only selected references are cited in
the CPG. To ensure that CPGs remain current, new data
are reviewed biannually by the GWCs and the Task Force
to determine if recommendations should be updated or
modiﬁed. In general, a target cycle of 5 years is planned
for full revisions (1).
Guideline-Directed Medical Therapy—Recognizing ad-
vances in medical therapy across the spectrum of car-
diovascular diseases, the Task Force designated the term
“guideline-directed medical therapy” (GDMT) to repre-
sent recommended medical therapy as deﬁned mainly by
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the clinical practice guidelines do not
lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons
of the treatments or strategies being evaluated.
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2648Class I measures, generally a combination of lifestyle
modiﬁcation and drug- and device-based therapeutics. As
medical science advances, GDMT evolves, and hence
GDMT is preferred to “optimal medical therapy.” For
GDMT and all other recommended drug treatment regi-
mens, the reader should conﬁrm the dosage with product
insert material and carefully evaluate for contraindica-
tions and possible drug interactions. Recommendations
are limited to treatments, drugs, and devices approved for
clinical use in the United States.
Class of Recommendation and Level of Evidence—Once
recommendations are written, the Class of Recommen-
dation (COR; i.e., the strength the GWC assigns to therecommendation, which encompasses the anticipated
magnitude and judged certainty of beneﬁt in proportion
to risk) is assigned by the GWC. Concurrently, the Level of
Evidence (LOE) rates the scientiﬁc evidence supporting
the effect of the intervention on the basis on the type,
quality, quantity, and consistency of data from clinical
trials and other reports (Table 1) (4). Unless otherwise
stated, recommendations are presented in order by the
COR and then the LOE. Where comparative data exist,
preferred strategies take precedence. When more than 1
drug, strategy, or therapy exists within the same COR and
LOE and there are no comparative data, options are listed
alphabetically.
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2649Relationships With Industry and Other Entities—The ACC
and AHA exclusively sponsor the work of GWCs without
commercial support, and members volunteer their time
for this activity. The Task Force makes every effort to
avoid actual, potential, or perceived conﬂicts of interest
that might arise through relationships with industry or
other entities (RWI). All GWC members and reviewers
are required to fully disclose current industry relation-
ships or personal interests from 12 months before initia-
tion of the writing effort. Management of RWI involves
selecting a balanced GWC and requires that both the
chair and a majority of GWC members have no relevant
RWI (see Appendix 1 for the deﬁnition of relevance). GWC
members are restricted with regard to writing or voting on
sections to which their RWI apply. In addition, for
transparency, GWC members’ comprehensive disclosure
information is available as an online supplement.
Comprehensive disclosure information for the Task
Force is available as an additional supplement. The Task
Force strives to avoid bias by selecting experts from a
broad array of backgrounds representing different
geographic regions, sexes, ethnicities, races, intellectual
perspectives/biases, and scopes of clinical practice.
Selected organizations and professional societies with
related interests and expertise are invited to participate
as partners or collaborators.
Individualizing Care in PatientsWith Associated Conditions
and Comorbidities—The ACC and AHA recognize the
complexity of managing patients with multiple conditions,
compared with managing patients with a single disease, and
the challenge is compounded when CPGs for evaluation or
treatment of several coexisting illnesses are discordant or
interacting (7). CPGs attempt to deﬁne practices that meet
the needs of patients in most, but not all, circumstances and
do not replace clinical judgment.
Clinical Implementation—Management in accordance
with CPG recommendations is effective only when
followed; therefore, to enhance their commitment to
treatment and compliance with lifestyle adjustment,
clinicians should engage the patient to participate
in selecting interventions on the basis of the pa-
tient’s individual values and preferences, taking associ-
ated conditions and comorbidities into consideration
(e.g., shared decision making). Consequently, there are
circumstances in which deviations from these guidelines
are appropriate.
The recommendations in this CPG are the ofﬁcial policy
of the ACC and AHA until they are superseded by a pub-
lished addendum, focused update, or revised full-text
CPG. The reader is encouraged to consult the full-text
CPG (8) for additional guidance and details about the
management of patients with non–ST-elevation acute
coronary syndrome (NSTE-ACS) because the executive
summary contains mainly the recommendations.Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this CPG are, whenever
possible, evidence based. An extensive evidence review
was conducted through October 2012, and other selected
references published through April 2014 were reviewed
by the GWC. Literature included was derived from
research involving human subjects, published in English,
and indexed in MEDLINE (through PubMed), EMBASE,
the Cochrane Library, Agency for Healthcare Research
and Quality Reports, and other selected databases rele-
vant to this CPG. The relevant data are included in evi-
dence tables in the Online Data Supplement. Key search
words included but were not limited to the following: acute
coronary syndrome, anticoagulant therapy, antihyperten-
sives, anti-ischemic therapy, antiplatelet therapy, antith-
rombotic therapy, beta blockers, biomarkers, calcium channel
blockers, cardiac rehabilitation, conservative management,
diabetes mellitus, glycoprotein IIb/IIIa inhibitors, heart fail-
ure, invasive strategy, lifestyle modiﬁcation, myocardial
infarction, nitrates, non-ST-elevation, P2Y12 receptor inhi-
bitor, percutaneous coronary intervention, renin-angiotensin-
aldosterone inhibitors, secondary prevention, smoking
cessation, statins, stent, thienopyridines, troponins, unstable
angina, and weight management. Additionally, the GWC
reviewed documents related to NSTE-ACS previously
published by the ACC and AHA. References selected and
published in this document are representative and not
all-inclusive.
1.2. Organization of the GWC
The GWC was composed of clinicians, cardiologists, in-
ternists, interventionists, surgeons, emergency medicine
specialists, family practitioners, and geriatricians. The
GWC included representatives from the ACC and AHA,
American Academy of Family Physicians, American
College of Emergency Physicians, American College
of Physicians, Society for Cardiovascular Angiography and
Interventions, and Society of Thoracic Surgeons.
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
nominated by the ACC and AHA; 1 reviewer each from the
American Academy of Family Physicians, American Col-
lege of Emergency Physicians, Society for Cardiovascular
Angiography and Interventions, and Society of Thoracic
Surgeons; and 37 individual content reviewers (including
members of the American Association of Clinical Chem-
istry, ACC Heart Failure and Transplant Section Leader-
ship Council, ACC Cardiovascular Imaging Section
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ship Council, ACC Prevention of Cardiovascular Disease
Committee, ACC Surgeons’ Council, Association of In-
ternational Governors, and Department of Health and
Human Services). Reviewers’ RWI information was
distributed to the GWC and is published in this document
(Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and the AHA and endorsed
by the American Association for Clinical Chemistry,
Society for Cardiovascular Angiography and Inter-
ventions, and the Society of Thoracic Surgeons.
1.4. Scope of the CPG
The 2014 NSTE-ACS CPG is a full revision of the 2007
ACCF/AHA CPG for the management of patients with
unstable angina (UA) and non–ST-elevation myocardial
infarction (NSTEMI) and the 2012 focused update (9). The
new title, “Non–ST-Elevation Acute Coronary Syn-
dromes,” emphasizes the continuum between UA and
NSTEMI. At presentation, patients with UA and NSTEMI
can be indistinguishable and are therefore considered
together in this CPG.
In the United States, NSTE-ACS affects >625,000 pa-
tients annually,* or almost three fourths of all patients
with acute coronary syndrome (ACS) (10). In selecting the
initial approach to care, the term “ischemia-guided
strategy” has replaced the previous descriptor, “initial
conservative management,” to more clearly convey the
physiological rationale of this approach.
The task of the 2014 GWC was to establish a contempo-
rary CPG for the optimal management of patients with
NSTE-ACS. It incorporates both established and new evi-
dence from published clinical trials, as well as information
from basic science and comprehensive review articles.
These recommendations were developed to guide the
clinician in improving outcomes for patients with NSTE-
ACS. Table 2 lists documents deemed pertinent to this
effort and is intended for use as a resource, thus obviating
the need to repeat extant CPG recommendations.
The GWC abbreviated the discussion sections to
include an explanation of salient information related to
the recommendations. In contrast to textbook declaratory
presentations, explanations were supplemented with ev-
idence tables. The GWC also provided a brief summary of
the relevant recommendations and references related to
secondary prevention rather than detailed reiteration.
Throughout, the goal was to provide the clinician with
concise, evidence-based contemporary recommendations*Estimate includes secondary discharge diagnoses.and the supporting documentation to encourage their
application.
2. OVERVIEW OF ACS
ACS has evolved as a useful operational term that refers to
a spectrum of conditions compatible with acute myocar-
dial ischemia and/or infarction that are usually due to an
abrupt reduction in coronary blood ﬂow (Figure 1).
3. INITIAL EVALUATION AND MANAGEMENT:
RECOMMENDATIONS
3.1. Clinical Assessment and Initial Evaluation
CLASS I
1. Patients with suspected ACS should be risk stratiﬁed based
on the likelihood of ACS and adverse outcome(s) to decide on
the need for hospitalization and assist in the selection of
treatment options (40–42). (Level of Evidence: B)
3.2. Emergency Department or Outpatient Facility Presentation
CLASS I
1. Patients with suspected ACS and high-risk features such as
continuing chest pain, severe dyspnea, syncope/presyncope,
or palpitations should be referred immediately to the
emergency department (ED) and transported by emergency
medical services when available. (Level of Evidence: C)
CLASS IIb
1. Patients with less severe symptoms may be considered for
referral to the ED, a chest pain unit, or a facility capable of
performing adequate evaluation depending on clinical cir-
cumstances. (Level of Evidence: C)3.3. Prognosis—Early Risk Stratiﬁcation
See Figure 2 and Table 3 for estimation at presentation of
death and nonfatal cardiac ischemic events. See Table 4
for a summary of recommendations from this section.
CLASS I
1. In patients with chest pain or other symptoms suggestive of
ACS, a 12-lead electrocardiogram (ECG) should be performed
and evaluated for ischemic changes within 10 minutes of
the patient’s arrival at an emergency facility (22). (Level of
Evidence: C)
2. If the initial ECG is not diagnostic but the patient remains
symptomatic and there is a high clinical suspicion for ACS,
serial ECGs (e.g., 15- to 30-minute intervals during the ﬁrst
hour) should be performed to detect ischemic changes.
(Level of Evidence: C)
3. Serial cardiac troponin I or T levels (when a contemporary
assay is used) should be obtained at presentation and 3 to 6
hours after symptom onset (see Section 3.4.1, Class I, #3
recommendation if time of symptom onset is unclear) in all
TABLE 2 Associated CPGs and Statements
Title Organization Publication Year (Reference)
CPGs
Stable ischemic heart disease ACC/AHA/AATS/PCNA/SCAI/STS 2014 (11)* 2012 (12)
Atrial ﬁbrillation AHA/ACC/HRS 2014 (13)
Assessment of cardiovascular risk ACC/AHA 2013 (14)
Heart failure ACC/AHA 2013 (15)
Lifestyle management to reduce cardiovascular risk AHA/ACC 2013 (16)
Management of overweight and obesity in adults AHA/ACC/TOS 2013 (17)
ST-elevation myocardial infarction ACC/AHA 2013 (18)
Treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults ACC/AHA 2013 (19)
Acute myocardial infarction in patients presenting with ST-segment elevation ESC 2012 (20)
Device-based therapy ACC/AHA/HRS 2013 (21)
Third universal deﬁnition of myocardial infarction ESC/ACC/AHA/WHF 2012 (22)
Acute coronary syndromes in patients presenting without persistent ST-segment elevation ESC 2011 (23)
Coronary artery bypass graft surgery ACC/AHA 2011 (24)
Hypertrophic cardiomyopathy ACC/AHA 2011 (25)
Effectiveness-based guidelines for the prevention of cardiovascular disease in women AHA/ACC 2011 (26)
Percutaneous coronary intervention ACC/AHA/SCAI 2011 (27)
Secondary prevention and risk reduction therapy for patients with coronary
and other atherosclerotic vascular disease
AHA/ACC 2011 (28)
Assessment of cardiovascular risk in asymptomatic adults ACC/AHA 2010 (29)
Myocardial revascularization ESC 2010 (30)
Unstable angina and non–ST-elevation myocardial infarction NICE 2010 (31)†
Guidelines for cardiopulmonary resuscitation and emergency cardiovascular
care—part 9: postcardiac arrest care
AHA 2010 (32)
Seventh report of the joint national committee on prevention, detection,
evaluation, and treatment of high blood pressure
NHLBI 2003 (33)
Statements
Key data elements and deﬁnitions for measuring the clinical management and
outcomes of patients with acute coronary syndromes and coronary artery disease
ACC/AHA 2013 (34)
Practical clinical considerations in the interpretation of troponin elevations ACC 2012 (35)
Testing of low-risk patients presenting to the emergency department with chest pain AHA 2010 (36)
Primary prevention of cardiovascular diseases in people with diabetes mellitus AHA/ADA 2007 (37)
Prevention and control of inﬂuenza CDC 2005 (38)
*The full-text SIHD CPG is from 2012 (12). A focused update was published in 2014 (11).
†Minor modiﬁcations were made in 2013. For a full explanation of the changes, see http://publications.nice.org.uk/unstable-angina-and-nstemi-cg94/changes-after-publication.
AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ADA, American Diabetes Association; AHA, American Heart Association; CDC, Centers
for Disease Control and Prevention; CPG, clinical practice guideline; ESC, European Society of Cardiology; HRS, Heart Rhythm Society; NHLBI, National Heart, Lung, and Blood Institute;
NICE, National Institute for Health and Clinical Excellence; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for Cardiovascular Angiography and Interventions; SIHD,
stable ischemic heart disease; STS, Society of Thoracic Surgeons; TOS, The Obesity Society; and WHF, World Heart Federation.
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2651patients who present with symptoms consistent with ACS to
identify a rising and/or falling pattern of values (22,43–48).
(Level of Evidence: A)
4. Additional troponin levels should be obtained beyond 6
hours after symptom onset (see Section 3.4.1, Class I, #3
recommendation if time of symptom onset is unclear) in
patients with normal troponin levels on serial examination
when changes on ECG and/or clinical presentation confer an
intermediate or high index of suspicion for ACS (22,49–51).
(Level of Evidence: A)5. Risk scores should be used to assess prognosis in patients
with NSTE-ACS (40–42,52–57). (Level of Evidence: A)
CLASS IIa
1. Risk-stratiﬁcation models can be useful in management
(40–42,52–58). (Level of Evidence: B)
2. It is reasonable to obtain supplemental electrocardiographic
leads V7 to V9 in patients whose initial ECG is nondiagnostic
and who are at intermediate/high risk of ACS (59–61).
(Level of Evidence: B)
FIGURE 1 Acute Coronary Syndromes
The top half of the ﬁgure illustrates the progression of plaque formation and onset and complications of NSTE-ACS, with management at each stage. The
numbered section of an artery depicts the process of atherogenesis from 1) normal artery to 2) extracellular lipid in the subintima to 3) ﬁbrofatty stage to
4) procoagulant expression and weakening of the ﬁbrous cap. ACS develops with 5) disruption of the ﬁbrous cap, which is the stimulus for thrombogenesis.
6) Thrombus resorption may be followed by collagen accumulation and smooth muscle cell growth. Thrombus formation and possible coronary vasospasm
reduce blood ﬂow in the affected coronary artery and cause ischemic chest pain. The bottom half of the ﬁgure illustrates the clinical, pathological,
electrocardiographic, and biomarker correlates in ACS and the general approach to management. Flow reduction may be related to a completely occlusive
thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Most patients with ST-elevation (thick white arrow in bottom
panel) develop QwMI, and a few (thin white arrow) develop NQMI. Those without ST-elevation have either UA or NSTEMI (thick red arrows), a distinction
based on cardiac biomarkers. Most patients presenting with NSTEMI develop NQMI; a few may develop QwMI. The spectrum of clinical presentations
including UA, NSTEMI, and STEMI is referred to as ACS. This NSTE-ACS CPG includes sections on initial management before NSTE-ACS, at the onset of
NSTE-ACS, and during the hospital phase. Secondary prevention and plans for long-term management begin early during the hospital phase. Patients with
noncardiac etiologies make up the largest group presenting to the ED with chest pain (dashed arrow).
*Elevated cardiac biomarker (e.g., troponin), Section 3.4.
ACS indicates acute coronary syndrome; CPG, clinical practice guideline; Dx, diagnosis; ECG, electrocardiogram; ED, emergency department; MI, myocardial
infarction; NQMI, non–Q-wavemyocardial infarction; NSTE-ACS, non–ST-elevation acute coronary syndromes;NSTEMI, non–ST-elevationmyocardial infarction;
QwMI, Q-wave myocardial infarction; STEMI, ST-elevation myocardial infarction; and UA, unstable angina.
Modiﬁed with permission from Libby et al. (39).
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FIGURE 2 Global Registry of Acute Coronary Events Risk Calculator for In-Hospital Mortality for Acute Coronary Syndrome
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TABLE 3 TIMI Risk Score* for NSTE-ACS
TIMI Risk
Score
All-Cause Mortality, New or Recurrent MI, or Severe
Recurrent Ischemia Requiring Urgent Revascularization
Through 14 d After Randomization, %
0–1 4.7
2 8.3
3 13.2
4 19.9
5 26.2
6–7 40.9
*The TIMI risk score is determined by the sum of the presence of 7 variables at
admission; 1 point is given for each of the following variables: $65 y of age; $3 risk
factors for CAD; prior coronary stenosis $50%; ST deviation on ECG; $2 anginal events
in prior 24 h; use of aspirin in prior 7 d; and elevated cardiac biomarkers.
CAD indicates coronary artery disease; ECG, electrocardiogram; MI, myocardial
infarction; NSTE-ACS, non–ST-elevation acute coronary syndromes; and TIMI, Throm-
bolysis In Myocardial Infarction.
Modiﬁed with permission from Antman et al. (40).
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1. Continuous monitoring with 12-lead ECG may be a
reasonable alternative in patients whose initial ECG is non-
diagnostic and who are at intermediate/high risk of ACS
(62,63). (Level of Evidence: B)
2. Measurement of B-type natriuretic peptide or N-terminal pro–
B-type natriuretic peptide may be considered to assess risk in
patients with suspected ACS (64–68). (Level of Evidence: B)
3.4. Cardiac Biomarkers and the Universal Deﬁnition of
Myocardial Infarction
See Table 5 for a summary of recommendations from this
section.
3.4.1. Biomarkers: Diagnosis
CLASS I
1. Cardiac-speciﬁc troponin (troponin I or T when a contem-
porary assay is used) levels should be measured atTABLE 4 Summary of Recommendations for Prognosis: Early Ri
Recommendations
Perform rapid determination of likelihood of ACS, including a 12-lead ECG within 10 m
emergency facility, in patients whose symptoms suggest ACS
Perform serial ECGs at 15- to 30-min intervals during the ﬁrst hour in symptomatic p
initial nondiagnostic ECG
Measure cardiac troponin (cTnI or cTnT) in all patients with symptoms consistent wit
Measure serial cardiac troponin I or T at presentation and 3–6 h after symptom onset
with symptoms consistent with ACS
Use risk scores to assess prognosis in patients with NSTE-ACS
Risk-stratiﬁcation models can be useful in management
Obtain supplemental electrocardiographic leads V7 to V9 in patients with initial nond
ECG at intermediate/high risk for ACS
Continuous monitoring with 12-lead ECG may be a reasonable alternative with initial
ECG in patients at intermediate/high risk for ACS
BNP or NT–pro-BNP may be considered to assess risk in patients with suspected ACS
*See Section 3.4.1, Class I, #3 recommendation if time of symptom onset is unclear.
ACS indicates acute coronary syndromes; BNP, B-type natriuretic peptide; COR, Class of Rec
LOE, Level of Evidence; N/A, not available; NSTE-ACS, nonST-elevation acute coronary synpresentation and 3 to 6 hours after symptom onset in all
patients who present with symptoms consistent with ACS to
identify a rising and/or falling pattern (22,43–48,70–74).
(Level of Evidence: A)
2. Additional troponin levels should be obtained beyond 6
hours after symptom onset in patients with normal troponins
on serial examination when electrocardiographic changes
and/or clinical presentation confer an intermediate or
high index of suspicion for ACS (22,49–51,75). (Level of
Evidence: A)
3. If the time of symptom onset is ambiguous, the time of
presentation should be considered the time of onset for
assessing troponin values (44,45,49). (Level of Evidence: A)
CLASS III: NO BENEFIT
1. With contemporary troponin assays, creatine kinase
myocardial isoenzyme (CK-MB) and myoglobin are not useful
for diagnosis of ACS (76–82). (Level of Evidence: A)3.4.2. Biomarkers: Prognosis
CLASS I
1. The presence and magnitude of troponin elevations are
useful for short- and long-term prognosis (48,50,83,84).
(Level of Evidence: B)
CLASS IIb
1. It may be reasonable to remeasure troponin once on day 3 or
day 4 in patients with a myocardial infarction (MI) as an in-
dex of infarct size and dynamics of necrosis (82,83). (Level
of Evidence: B)
2. Use of selected newer biomarkers, especially B-type
natriuretic peptide, may be reasonable to provide
additional prognostic information (64,65,85–89). (Level of
Evidence: B)sk Stratiﬁcation
COR LOE References
in of arrival at an I C (22)
atients with I C N/A
h ACS* I A (22,43–48)
* in all patients I A (22,49–51)
I A (40–42,52–57)
IIa B (40–42,52–58)
iagnostic IIa B (59–61)
nondiagnostic IIb B (62,63)
IIb B (64–68)
ommendation; cTnI, cardiac troponin I; cTnT, cardiac troponin T; ECG, electrocardiogram;
dromes; and NT–pro-BNP, N-terminal pro–B-type natriuretic peptide.
TABLE 5 Summary of Recommendations for Cardiac Biomarkers and the Universal Deﬁnition of MI
Recommendations COR LOE References
Diagnosis
Measure cardiac-speciﬁc troponin (troponin I or T) at presentation and 3—6 h after symptom
onset in all patients with suspected ACS to identify pattern of values
I A (22,43–48,70–74)
Obtain additional troponin levels beyond 6 h in patients with initial normal serial troponins with
electrocardiographic changes and/or intermediate/high risk clinical features
I A (22,49–51,75)
Consider time of presentation the time of onset with ambiguous symptom onset for assessing
troponin values
I A (44,45,49)
With contemporary troponin assays, CK-MB and myoglobin are not useful for diagnosis of ACS III: No Beneﬁt A (76–82)
Prognosis
Troponin elevations are useful for short- and long-term prognosis I B (48,50,83,84)
Remeasurement of troponin value once on d 3 or 4 in patients with MI may be reasonable
as an index of infarct size and dynamics of necrosis
IIb B (82,83)
BNP may be reasonable for additional prognostic information IIb B (64,65,85–89)
ACS indicates acute coronary syndromes; BNP, B-type natriuretic peptide; CK-MB, creatine kinase myocardial isoenzyme; COR, Class of Recommendation; LOE, Level of Evidence; and
MI, myocardial infarction.
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CLASS IIa
1. It is reasonable to observe patients with symptoms consis-
tent with ACS without objective evidence of myocardial
ischemia (nonischemic initial ECG and normal cardiac
troponin) in a chest pain unit or telemetry unit with serial
ECGs and cardiac troponin at 3- to 6-hour intervals (90–94).
(Level of Evidence: B)
2. It is reasonable for patients with possible ACS who have
normal serial ECGs and cardiac troponins to have a treadmill
ECG (93–95) (Level of Evidence: A), stress myocardial
perfusion imaging (93), or stress echocardiography (96,97)
before discharge or within 72 hours after discharge. (Level
of Evidence: B)
3. In patients with possible ACS and a normal ECG, normal
cardiac troponins, and no history of coronary artery dis-
ease (CAD), it is reasonable to initially perform (without
serial ECGs and troponins) coronary computed tomogra-
phy angiography to assess coronary artery anatomy
(98–100) (Level of Evidence: A) or rest myocardial per-
fusion imaging with a technetium-99m radiopharmaceu-
tical to exclude myocardial ischemia (101,102). (Level of
Evidence: B)
4. It is reasonable to give low-risk patients who are referred for
outpatient testing daily aspirin, short-acting nitroglycerin,
and other medication if appropriate (e.g., beta blockers),
with instructions about activity level and clinician follow-up.
(Level of Evidence: C)4. EARLY HOSPITAL CARE: RECOMMENDATIONS
See Table 6 for a summary of recommendations from this
section.4.1. Standard Medical Therapies
4.1.1. Oxygen
CLASS I
1. Supplemental oxygen should be administered to patients
with NSTE-ACS with arterial oxygen saturation less than
90%, respiratory distress, or other high-risk features of
hypoxemia. (Level of Evidence: C)
4.1.2. Nitrates
CLASS I
1. Patients with NSTE-ACS with continuing ischemic pain
should receive sublingual nitroglycerin (0.3 mg–0.4 mg)
every 5 minutes for up to 3 doses, after which an assess-
ment should be made about the need for intravenous
nitroglycerin if not contraindicated (103–105). (Level of
Evidence: C)
2. Intravenous nitroglycerin is indicated for patients with
NSTE-ACS for the treatment of persistent ischemia, heart
failure (HF), or hypertension (106–111). (Level of Evidence: B)
CLASS III: HARM
1. Nitrates should not be administered to patients with NSTE-
ACS who recently received a phosphodiesterase inhibitor,
especially within 24 hours of sildenaﬁl or vardenaﬁl, or
within 48 hours of tadalaﬁl (112–114). (Level of Evidence: B)
4.1.3. Analgesic Therapy
CLASS IIb
1. In the absence of contraindications, it may be reasonable to
administer morphine sulfate intravenously to patients with
NSTE-ACS if there is continued ischemic chest pain despite
treatment with maximally tolerated anti-ischemic medica-
tions (115,116). (Level of Evidence: B)
TABLE 6 Summary of Recommendations for Early Hospital Care
Recommendations COR LOE References
Oxygen
Administer supplemental oxygen only with oxygen saturation <90%, respiratory distress, or other
high-risk features for hypoxemia
I C N/A
Nitrates
Administer sublingual NTG every 5 min  3 for continuing ischemic pain and then assess need for IV NTG I C (103–105)
Administer IV NTG for persistent ischemia, HF, or hypertension I B (106–111)
Nitrates are contraindicated with recent use of a phosphodiesterase inhibitor III: Harm B (112–114)
Analgesic therapy
IV morphine sulfate may be reasonable for continued ischemic chest pain despite maximally tolerated
anti-ischemic medications
IIb B (115,116)
NSAIDs (except aspirin) should not be initiated and should be discontinued during hospitalization for
NSTE-ACS because of the increased risk of MACE associated with their use
III: Harm B (117,118)
Beta-adrenergic blockers
Initiate oral beta blockers within the ﬁrst 24 h in the absence of HF, low-output state, risk for cardiogenic
shock, or other contraindications to beta blockade
I A (119–121)
Use of sustained-release metoprolol succinate, carvedilol, or bisoprolol is recommended for beta-blocker
therapy with concomitant NSTE-ACS, stabilized HF, and reduced systolic function
I C N/A
Re-evaluate to determine subsequent eligibility in patients with initial contraindications to beta blockers I C N/A
It is reasonable to continue beta-blocker therapy in patients with normal LV function with NSTE-ACS IIa C (120,122)
IV beta blockers are potentially harmful when risk factors for shock are present III: Harm B (123)
CCBs
Administer initial therapy with nondihydropyridine CCBs with recurrent ischemia and contraindications
to beta blockers in the absence of LV dysfunction, increased risk for cardiogenic shock, PR interval
>0.24 s, or second- or third-degree atrioventricular block without a cardiac pacemaker
I B (124–126)
Administer oral nondihydropyridine calcium antagonists with recurrent ischemia after use of beta blocker
and nitrates in the absence of contraindications
I C N/A
CCBs are recommended for ischemic symptoms when beta blockers are not successful, are contraindicated,
or cause unacceptable side effects*
I C N/A
Long-acting CCBs and nitrates are recommended for patients with coronary artery spasm I C N/A
Immediate-release nifedipine is contraindicated in the absence of a beta blocker III: Harm B (127,128)
Cholesterol management
Initiate or continue high-intensity statin therapy in patients with no contraindications I A (129–133)
Obtain a fasting lipid proﬁle, preferably within 24 h IIa C N/A
*Short-acting dihydropyridine calcium channel antagonists should be avoided.
CCB indicates calcium channel blocker; COR, Class of Recommendation; HF, heart failure; IV, intravenous; LOE, Level of Evidence; LV, left ventricular; MACE, major adverse cardiac
event; N/A, not available; NSAIDs, nonsteroidal anti-inﬂammatory drugs; NSTE-ACS, non–ST-elevation acute coronary syndromes; and NTG, nitroglycerin.
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1. Nonsteroidal anti-inﬂammatory drugs (NSAIDs) (except
aspirin) should not be initiated and should be discontinued
during hospitalization for NSTE-ACS because of the
increased risk of MACE associated with their use (117,118).
(Level of Evidence: B)
4.1.4. Beta-Adrenergic Blockers
CLASS I
1. Oral beta-blocker therapy should be initiated within the ﬁrst
24 hours in patients who do not have any of the following:
1) signs of HF, 2) evidence of low-output state, 3) increased
risk for cardiogenic shock, or 4) other contraindications tobeta blockade (e.g., PR interval >0.24 second, second- or
third-degree heart block without a cardiac pacemaker, active
asthma, or reactive airway disease) (119–121). (Level of
Evidence: A)
2. In patients with concomitant NSTE-ACS, stabilized HF, and
reduced systolic function, it is recommended to continue
beta-blocker therapy with 1 of the 3 drugs proven to
reduce mortality in patients with HF: sustained-release
metoprolol succinate, carvedilol, or bisoprolol. (Level of
Evidence: C)
3. Patients with documented contraindications to beta blockers
in the ﬁrst 24 hours of NSTE-ACS should be reevaluated to
determine their subsequent eligibility. (Level of Evidence: C)
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1. It is reasonable to continue beta-blocker therapy in patients
with normal left ventricular (LV) function with NSTE-ACS
(120,122). (Level of Evidence: C)
CLASS III: HARM
1. Administration of intravenous beta blockers is potentially
harmful in patients with NSTE-ACS who have risk factors for
shock (123). (Level of Evidence: B)
4.1.5. Calcium Channel Blockers
CLASS I
1. In patients with NSTE-ACS, continuing or frequently recurring
ischemia, and a contraindication to beta blockers, a non-
dihydropyridine calcium channel blocker (CCB) (e.g., verap-
amil or diltiazem) should be given as initial therapy in the
absence of clinically signiﬁcant LV dysfunction, increased risk
for cardiogenic shock, PR interval greater than 0.24 second,
or second- or third-degree atrioventricular block without a
cardiac pacemaker (124–126). (Level of Evidence: B)
2. Oral nondihydropyridine calcium antagonists are recom-
mended in patients with NSTE-ACS who have recurrent
ischemia in the absence of contraindications, after appro-
priate use of beta blockers and nitrates. (Level of Evidence: C)
3. CCBsy are recommended for ischemic symptoms when beta
blockers are not successful, are contraindicated, or cause
unacceptable side effects. (Level of Evidence: C)
4. Long-acting CCBs and nitrates are recommended in patients
with coronary artery spasm. (Level of Evidence: C)
CLASS III: HARM
1. Immediate-release nifedipine should not be administered to
patients with NSTE-ACS in the absence of beta-blocker
therapy (127,128). (Level of Evidence: B)
4.1.6. Cholesterol Management
CLASS I
1. High-intensity statin therapy should be initiated or
continued in all patients with NSTE-ACS and no contraindi-
cations to its use (129–133). (Level of Evidence: A)
CLASS IIa
1. It is reasonable to obtain a fasting lipid proﬁle in patients
with NSTE-ACS, preferably within 24 hours of presentation.
(Level of Evidence: C)
4.2. Inhibitors of the Renin-Angiotensin-Aldosterone System
CLASS I
1. Angiotensin-converting enzyme (ACE) inhibitors should be
started and continued indeﬁnitely in all patients with leftyShort-acting dihydropyridine calcium channel antagonists should be avoided.ventricular ejection fraction (LVEF) less than 0.40 and in
those with hypertension, diabetes mellitus, or stable chronic
kidney disease (CKD) (Section 7.6), unless contraindicated
(134,135). (Level of Evidence: A)
2. Angiotensin receptor blockers are recommended in patients
with HF or MI with LVEF less than 0.40 who are ACE inhibitor
intolerant (136,137). (Level of Evidence: A)
3. Aldosterone blockade is recommended in post–MI patients
who are without signiﬁcant renal dysfunction (creatinine
>2.5 mg/dL in men or >2.0 mg/dL in women) or hyper-
kalemia (K+ >5.0 mEq/L) who are receiving therapeutic
doses of ACE inhibitor and beta blocker and have a LVEF
0.40 or less, diabetes mellitus, or HF (138). (Level of
Evidence: A)
CLASS IIa
1. Angiotensin receptor blockers are reasonable in other pa-
tients with cardiac or other vascular disease who are ACE
inhibitor intolerant (139). (Level of Evidence: B)
CLASS IIb
1. ACE inhibitors may be reasonable in all other patients
with cardiac or other vascular disease (140,141). (Level of
Evidence: B)4.3. Initial Antiplatelet/Anticoagulant Therapy in Patients With
Deﬁnite or Likely NSTE-ACS
4.3.1. Initial Oral and Intravenous Antiplatelet Therapy in
Patients With Deﬁnite or Likely NSTE-ACS Treated With an
Initial Invasive or Ischemia-Guided Strategy
See Table 7 for a summary of recommendations from this
section.
CLASS Iz
1. Non–enteric-coated, chewable aspirin (162 mg to 325 mg)
should be given to all patients with NSTE-ACS without
contraindications as soon as possible after presentation,
and a maintenance dose of aspirin (81 mg/d to 325 mg/d)
should be continued indeﬁnitely (142–144,147,363). (Level
of Evidence: A)
2. In patients with NSTE-ACS who are unable to take aspirin
because of hypersensitivity or major gastrointestinal intol-
erance, a loading dose of clopidogrel followed by a daily
maintenance dose should be administered (145). (Level of
Evidence: B)
3. A P2Y12 inhibitor (either clopidogrel or ticagrelor) in addition
to aspirin should be administered for up to 12 months to all
patients with NSTE-ACS without contraindications who arezSee Section 5.1 for recommendations at the time of PCI.
TABLE 7
Summary of Recommendations for Initial Antiplatelet/Anticoagulant Therapy in Patients With Deﬁnite or Likely
NSTE-ACS and PCI
Recommendations Dosing and Special Considerations COR LOE References
Aspirin
Non–enteric-coated aspirin to all patients promptly
after presentation
162 mg–325 mg I A (142–144)
Aspirin maintenance dose continued indeﬁnitely 81 mg/d–325 mg/d* I A (142–144,147,363)
P2Y12 inhibitors
Clopidogrel loading dose followed by daily maintenance
dose in patients unable to take aspirin
75 mg I B (145)
P2Y12 inhibitor, in addition to aspirin, for up to 12 mo
for patients treated initially with either an early
invasive or initial ischemia-guided strategy:
 Clopidogrel
 Ticagrelor*
I B
300-mg or 600-mg loading dose, then 75 mg/d (143,146)
180-mg loading dose, then 90 mg BID (147,148)
P2Y12 inhibitor therapy (clopidogrel, prasugrel, or
ticagrelor) continued for at least 12 mo in
post–PCI patients treated with coronary stents
N/A I B (147,169–172)
Ticagrelor in preference to clopidogrel for patients
treated with an early invasive or ischemia-guided
strategy
N/A IIa B (147,148)
GP IIb/IIIa inhibitors
GP IIb/IIIa inhibitor in patients treated with an early
invasive strategy and DAPT with intermediate/high-risk
features (e.g., positive troponin)
 Preferred options are eptiﬁbatide or tiroﬁban IIb B (41,149,150)
Parenteral anticoagulant and ﬁbrinolytic therapy
SC enoxaparin for duration of hospitalization or until PCI
is performed
 1 mg/kg SC every 12 h (reduce dose to
1 mg/kg/d SC in patients with CrCl
<30 mL/min)
 Initial 30 mg IV loading dose in selected patients
I A (151–153)
Bivalirudin until diagnostic angiography or PCI is
performed in patients with early invasive strategy only
 Loading dose 0.10 mg/kg loading dose
followed by 0.25 mg/kg/h
 Only provisional use of GP IIb/IIIa inhibitor
in patients also treated with DAPT
I B (146,147,154,155)
SC fondaparinux for the duration of hospitalization or
until PCI is performed
 2.5 mg SC daily I B (156–158)
Administer additional anticoagulant with anti-IIa activity
if PCI is performed while patient is on fondaparinux
N/A I B (157–159)
IV UFH for 48 h or until PCI is performed  Initial loading dose 60 IU/kg (max
4,000 IU) with initial infusion 12 IU/kg/h
(max 1,000 IU/h)
 Adjusted to therapeutic aPTT range
I B (160–166)
IV ﬁbrinolytic treatment not recommended in patients
with NSTE-ACS
N/A III: Harm A (167,168)
See Section 5.1 for recommendations on antiplatelet/anticoagulant therapy at the time of PCI and Sections 6.2 and 6.3 for recommendations on posthospital therapy.
*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily (144).
aPTT indicates activated partial thromboplastin time; BID, twice daily; COR, Class of Recommendation; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; GP, glycoprotein;
IV, intravenous; LOE, Level of Evidence; max, maximum; N/A, not available; NSTE-ACS, non–ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention; SC,
subcutaneous; and UFH, unfractionated heparin.
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strategy. Options include:
 Clopidogrel: 300-mg or 600-mg loading dose, then 75
mg daily (143,146) (Level of Evidence: B)
 Ticagrelork: 180-mg loading dose, then 90 mg twice daily
(147,148) (Level of Evidence: B)xSee Section 4.3.1.2 in the full-text CPG for prasugrel indications in either an
early invasive or ischemia-guided strategy.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (144).CLASS IIa
1. It is reasonable to use ticagrelor in preference to clopidogrel
for P2Y12 treatment in patients with NSTE-ACS who undergo
an early invasive or ischemia-guided strategy (147,148).
(Level of Evidence: B)
CLASS IIb
1. In patients with NSTE-ACS treated with an early invasive
strategy and dual antiplatelet therapy (DAPT) with
intermediate/high-risk features (e.g., positive troponin), a
glycoprotein (GP) IIb/IIIa inhibitor may be considered as part
of initial antiplatelet therapy. Preferred options are eptiﬁ-
batide or tiroﬁban (41,149,150). (Level of Evidence: B)
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Deﬁnite NSTE-ACS
See Table 7 for a summary of recommendations from this
section.
CLASS Iz
1. In patients with NSTE-ACS, anticoagulation, in addition to
antiplatelet therapy, is recommended for all patients irre-
spective of initial treatment strategy. Treatment options
include:
 Enoxaparin: 1 mg/kg subcutaneous (SC) every 12 hours
(reduce dose to 1 mg/kg SC once daily in patients with
creatinine clearance [CrCl] <30 mL/min), continued for
the duration of hospitalization or until percutaneous
coronary intervention (PCI) is performed. An initial in-
travenous loading dose of 30 mg has been used in
selected patients (151–153). (Level of Evidence: A)
 Bivalirudin: 0.10 mg/kg loading dose followed by 0.25
mg/kg per hour (only in patients managed with an early
invasive strategy), continued until diagnostic angiography
or PCI, with only provisional use of GP IIb/IIIa inhibitor,
provided the patient is also treated with DAPT
(146,147,154,155). (Level of Evidence: B)
 Fondaparinux: 2.5 mg SC daily, continued for the duration
of hospitalization or until PCI is performed (156–158).
(Level of Evidence: B)
 If PCI is performed while the patient is on fondaparinux,
an additional anticoagulant with anti-IIa activity (either
UFH or bivalirudin) should be administered because of
the risk of catheter thrombosis (157–159). (Level of
Evidence: B)
 UFH IV: initial loading dose of 60 IU/kg (maximum 4,000
IU) with initial infusion of 12 IU/kg per hour (maximum
1,000 IU/h) adjusted per activated partial thrombo-
plastin time to maintain therapeutic anticoagulation ac-
cording to the speciﬁc hospital protocol, continued for
48 hours or until PCI is performed (160–166). (Level of
Evidence: B)
CLASS III: HARM
1. In patients with NSTE-ACS (i.e., without ST-elevation, true
posterior MI, or left bundle-branch block not known to be
old), intravenous ﬁbrinolytic therapy should not be used
(167,168). (Level of Evidence: A)4.4. Ischemia-Guided Strategy Versus Early
Invasive Strategies
See Figure 3 for the management algorithm for ischemia-
guided versus early invasive strategy.zSee Section 5.1 for recommendations at the time of PCI.4.4.1. Early Invasive and Ischemia-Guided Strategies
For deﬁnitions of invasive and ischemia-guided strate-
gies, see Table 8.
CLASS I
1. An urgent/immediate invasive strategy (diagnostic angiog-
raphy with intent to perform revascularization if appropriate
based on coronary anatomy) is indicated in patients (men
and women{) with NSTE-ACS who have refractory angina or
hemodynamic or electrical instability (without serious
comorbidities or contraindications to such procedures)
(40,42,173,174). (Level of Evidence: A)
2. An early invasive strategy (diagnostic angiography with
intent to perform revascularization if appropriate based
on coronary anatomy) is indicated in initially stabilized
patients with NSTE-ACS (without serious comorbidities or
contraindications to such procedures) who have an elevated
risk for clinical events (Table 8) (40,42,173–177). (Level of
Evidence: B)
CLASS IIa
1. It is reasonable to choose an early invasive strategy (within
24 hours of admission) over a delayed invasive strategy
(within 24 to 72 hours) for initially stabilized high-risk pa-
tients with NSTE-ACS. For those not at high/intermediate
risk, a delayed invasive approach is reasonable (173). (Level
of Evidence: B)
CLASS IIb
1. In initially stabilized patients, an ischemia-guided strategy
may be considered for patients with NSTE-ACS (without
serious comorbidities or contraindications to this approach)
who have an elevated risk for clinical events (174,175,177).
(Level of Evidence: B)
2. The decision to implement an ischemia-guided strategy in initially
stabilized patients (without serious comorbidities or contraindi-
cations to this approach) may be reasonable after considering
clinician and patient preference. (Level of Evidence: C)
CLASS III: NO BENEFIT
1. An early invasive strategy (i.e., diagnostic angiography with
intent to perform revascularization) is not recommended in
patients with:
a. Extensive comorbidities (e.g., hepatic, renal, pulmonary
failure; cancer), in whom the risks of revascularization and
comorbid conditions are likely to outweigh the beneﬁts of
revascularization. (Level of Evidence: C)
b. Acute chest pain and a low likelihood of ACS who
are troponin-negative (Level of Evidence: C), especially
women (178). (Level of Evidence: B){See Section 7.7 for additional information on women.
FIGURE 3 Algorithm for Management of Patients With Deﬁnite or Likely NSTE-ACS*
*See corresponding full-sentence recommendations and their explanatory footnotes.
†In patients who have been treated with fondaparinux (as upfront therapy) who are undergoing PCI, an additional anticoagulant with anti-IIa activity should
be administered at the time of PCI because of the risk of catheter thrombosis.
ASA indicates aspirin; CABG, coronary artery bypass graft; cath, catheter; COR, Class of Recommendation; DAPT, dual antiplatelet therapy; GPI, glycoprotein
IIb/IIIa inhibitor; LOE, Level of Evidence; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; pts, patients; and
UFH, unfractionated heparin.
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TABLE 8
Factors Associated With Appropriate Selection of Early Invasive Strategy or Ischemia-Guided Strategy in
Patients With NSTE-ACS
Immediate invasive (within 2 h) Refractory angina
Signs or symptoms of HF or new or worsening mitral regurgitation
Hemodynamic instability
Recurrent angina or ischemia at rest or with low-level activities despite intensive medical therapy
Sustained VT or VF
Ischemia-guided strategy Low-risk score (e.g., TIMI [0 or 1], GRACE [<109])
Low-risk Tn-negative female patients
Patient or clinician preference in the absence of high-risk features
Early invasive (within 24 h) None of the above, but GRACE risk score >140
Temporal change in Tn (Section 3.4)
New or presumably new ST depression
Delayed invasive (within 2572 h) None of the above but diabetes mellitus
Renal insufﬁciency (GFR <60 mL/min/1.73 m2)
Reduced LV systolic function (EF <0.40)
Early postinfarction angina
PCI within 6 mo
Prior CABG
GRACE risk score 109–140; TIMI score $2
CABG indicates coronary artery bypass graft; EF, ejection fraction; GFR, glomerular ﬁltration rate; GRACE, Global Registry of Acute Coronary Events; HF, heart failure; LV, left
ventricular; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction; Tn, troponin; VF, ventricular
ﬁbrillation; and VT, ventricular tachycardia.
#Patients should receive a loading dose of prasugrel provided that they were
not pretreated with another P2Y12 receptor inhibitor.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (144).
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Ischemia-Guided Strategy of NSTE-ACS
CLASS I
1. Noninvasive stress testing is recommended in low- and
intermediate-risk patients who have been free of ischemia at
rest or with low-level activity for a minimum of 12 to 24
hours (179–183). (Level of Evidence: B)
2. Treadmill exercise testing is useful in patients able to exercise
in whom the ECG is free of resting ST changes that may
interfere with interpretation (179–182). (Level of Evidence: C)
3. Stress testing with an imaging modality should be used in
patients who are able to exercise but have ST changes on
resting ECG that may interfere with interpretation. In patients
undergoing a low-level exercise test, an imagingmodality can
add prognostic information (179–182). (Level of Evidence: B)
4. Pharmacological stress testing with imaging is recom-
mended when physical limitations preclude adequate exer-
cise stress. (Level of Evidence: C)
5. A noninvasive imaging test is recommended to evaluate LV
function in patients with deﬁnite ACS (179–182). (Level of
Evidence: C)
5. MYOCARDIAL REVASCULARIZATION:
RECOMMENDATIONS
5.1. PCI—General Considerations
CLASS IIb
1. A strategy of multivessel PCI, in contrast to culprit
lesiononly PCI, may be reasonable in patients undergoingcoronary revascularization as part of treatment for
NSTE-ACS (169,184–189). (Level of Evidence: B)5.1.1. PCI—Oral and Intravenous Antiplatelet Agents
CLASS I
1. Patients already taking daily aspirin before PCI should take
81 mg to 325 mg non–enteric-coated aspirin before PCI
(27,190–192). (Level of Evidence: B)
2. Patients not on aspirin therapy should be given nonenteric-
coated aspirin 325 mg as soon as possible before PCI
(27,190–192). (Level of Evidence: B)
3. After PCI, aspirin should be continued indeﬁnitely at a dose
of 81 mg to 325 mg daily (28,142,193). (Level of Evidence: B)
4. A loading dose of a P2Y12 receptor inhibitor should be given
before the procedure in patients undergoing PCI with
stenting (27,147,170,172,194–197). (Level of Evidence: A)
Options include:
a. Clopidogrel: 600 mg (170,194–196,198–200) (Level of
Evidence: B) or
b. Prasugrel#: 60 mg (172) (Level of Evidence: B) or
c. Ticagrelork: 180 mg (147) (Level of Evidence: B)
TABLE 9 Dosing of Parenteral Anticoagulants During PCI
Drug*
In Patients Who Have Received
Prior Anticoagulant Therapy
In Patients Who Have Not Received
Prior Anticoagulant Therapy
Enoxaparin  For prior treatment with enoxaparin, if last SC dose was administered
812 h earlier or if <2 therapeutic SC doses of enoxaparin have been
administered, an IV dose of enoxaparin 0.3 mg/kg should be given
 If the last SC dose was administered within prior 8 h, no additional
enoxaparin should be given
 0.5 mg/kg–0.75 mg/kg IV loading dose
Bivalirudin  For patients who have received UFH, wait 30 min, then give
0.75 mg/kg IV loading dose, then 1.75 mg/kg/h IV infusion
 For patients already receiving bivalirudin infusion, give additional
loading dose 0.5 mg/kg and increase infusion to 1.75 mg/kg/h
during PCI
 0.75 mg/kg loading dose, 1.75 mg/kg/h IV infusion
Fondaparinux  For prior treatment with fondaparinux, administer additional IV
treatment with anticoagulant possessing anti-IIa activity, considering
whether GPI receptor antagonists have been administered
N/A
UFH  IV GPI planned: additional UFH as needed (e.g., 2,000–5,000 U)
to achieve ACT of 200–250 s
 No IV GPI planned: additional UFH as needed (e.g., 2,000–5,000 U)
to achieve ACT of 250–300 s for HemoTec, 300–350 s for Hemochron
 IV GPI planned: 50–70 U/kg loading dose to achieve ACT
of 200–250 s
 No IV GPI planned: 70–100 U/kg loading dose to achieve
target ACT of 250–300 s for HemoTec, 300–350 s
for Hemochron
*Drugs presented in order of the COR and then the LOE as noted in the Preamble. When more than 1 drug exists within the same LOE, and there are no comparative data, then the drugs
are listed alphabetically.
ACT indicates activated clotting time; COR, Class of Recommendation; GPI, glycoprotein IIb/IIIa inhibitor; IV, intravenous; LOE, Level of Evidence; N/A, not applicable; PCI,
percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin.
Modiﬁed from Levine et al. (27).
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troponin) who are not adequately pretreated with clopidogrel
or ticagrelor, it is useful to administer a GP IIb/IIIa inhibitor
(abciximab, double-bolus eptiﬁbatide, or high-dose bolus
tiroﬁban) at the time of PCI (201–204). (Level of Evidence: A)
6. In patients receiving a stent (bare-metal stent or drug-eluting
stent [DES]) during PCI for NSTE-ACS, P2Y12 inhibitor therapy
should be given for at least 12 months (169). Options include:
a. Clopidogrel: 75 mg daily (170,171) (Level of Evidence: B) or
b. Prasugrel#: 10 mg daily (172) (Level of Evidence: B) or
c. Ticagrelork: 90 mg twice daily (147) (Level of Evidence: B)
CLASS IIa
1. It is reasonable to choose ticagrelor over clopidogrel for
P2Y12 inhibition treatment in patients with NSTE-ACS
treated with an early invasive strategy and/or coronary
stenting (147,148). (Level of Evidence: B)
2. It is reasonable to choose prasugrel over clopidogrel for
P2Y12 treatment in patients with NSTE-ACS who undergo PCI
who are not at high risk of bleeding complications (172,205).
(Level of Evidence: B)
3. In patients with NSTE-ACS and high-risk features (e.g., elevated
troponin) treated with UFH and adequately pretreated with
clopidogrel, it is reasonable to administer a GP IIb/IIIa inhibitor
(abciximab, double-bolus eptiﬁbatide, or high-bolus dose
tiroﬁban) at the time of PCI (206–208). (Level of Evidence: B)#Patients should receive a loading dose of prasugrel provided that they were
not pretreated with another P2Y12 receptor inhibitor.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (144).4. After PCI, it is reasonable to use 81 mg per day of aspirin in
preference to higher maintenance doses (170,190,209–212).
(Level of Evidence: B)
5. If the risk of morbidity from bleeding outweighs the antici-
pated beneﬁt of a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation
(e.g., <12 months) of P2Y12 inhibitor therapy is reasonable
(169). (Level of Evidence: C)
CLASS IIb
1. Continuation of DAPT beyond 12 months may be considered in
patients undergoing stent implantation. (Level of Evidence: C)
CLASS III: HARM
1. Prasugrel should not be administered to patients with a prior
history of stroke or transient ischemic attack (172). (Level of
Evidence: B)
5.1.1.1. PCI—GP IIb/IIIa Inhibitors
CLASS I
1. In patients with NSTE-ACS and high-risk features (e.g.,
elevated troponin) and not adequately pretreated with clo-
pidogrel or ticagrelor, it is useful to administer a GP IIb/IIIa
inhibitor (abciximab, double-bolus eptiﬁbatide, or high-dose
bolus tiroﬁban) at the time of PCI (201–204). (Level of
Evidence: A)
CLASS IIa
1. In patients with NSTE-ACS and high-risk features (e.g.,
elevated troponin) treated with UFH and adequately pre-
treated with clopidogrel, it is reasonable to administer a GP
IIb/IIIa inhibitor (abciximab, double-bolus eptiﬁbatide, or
high-dose bolus tiroﬁban) at the time of PCI (206,207).
(Level of Evidence: B)
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See Table 9 for dosing information on dosing of parenteral
anticoagulants during PCI.
CLASS I
1. An anticoagulant should be administered to patients with
NSTE-ACS undergoing PCI to reduce the risk of intracoronary
and catheter thrombus formation. (Level of Evidence: C)
2. Intravenous UFH is useful in patients with NSTE-ACS
undergoing PCI. (Level of Evidence: C)
3. Bivalirudin is useful as an anticoagulant with or without prior
treatment with UFH in patients with NSTE-ACS undergoing
PCI (154,213–217). (Level of Evidence: B)
4. An additional dose of 0.3 mg/kg IV enoxaparin should be
administered at the time of PCI to patients with NSTE-ACS
who have received fewer than 2 therapeutic subcutaneous
doses (e.g., 1 mg/kg SC) or received the last subcutaneous
enoxaparin dose 8 to 12 hours before PCI (152,218–222).
(Level of Evidence: B)
5. If PCI is performed while the patient is on fondaparinux, an
additional 85 IU/kg of UFH should be given intravenously
immediately before PCI because of the risk of catheter
thrombosis (60 IU/kg IV if a GP IIb/IIIa inhibitor used with
UFH dosing based on the target-activated clotting time)
(27,157–159,223). (Level of Evidence: B)
6. In patients with NSTE-ACS, anticoagulant therapy should be
discontinued after PCI unless there is a compelling reason to
continue such therapy. (Level of Evidence: C)
CLASS IIa
1. In patients with NSTE-ACS undergoing PCI who are at high
risk of bleeding, it is reasonable to use bivalirudin mono-
therapy in preference to the combination of UFH and a GP
IIb/IIIa receptor antagonist (154,215). (Level of Evidence: B)
CLASS IIb
1. Performance of PCI with enoxaparin may be reasonable in
patients treated with upstream subcutaneous enoxaparin for
NSTE-ACS (27,152,218–221,224,225). (Level of Evidence: B)
CLASS III: HARM
1. Fondaparinux should not be used as the sole anticoagulant
to support PCI in patients with NSTE-ACS due to an in-
creased risk of catheter thrombosis (27,157–159). (Level of
Evidence: B)
5.2. Timing of Urgent Coronary Artery Bypass Graft in Patients
With NSTE-ACS in Relation to Use of Antiplatelet Agents
CLASS I
1. Non–enteric-coated aspirin (81 mg to 325 mg daily) should
be administered preoperatively to patients undergoing
coronary artery bypass graft (CABG) (226–228). (Level of
Evidence: B)2. In patients referred for elective CABG, clopidogrel and
ticagrelor should be discontinued for at least 5 days before
surgery (24,229–231) (Level of Evidence: B) and prasugrel for
at least 7 days before surgery (9,232). (Level of Evidence: C)
3. In patients referred for urgent CABG, clopidogrel and tica-
grelor should be discontinued for at least 24 hours to reduce
major bleeding (9,230,233–235). (Level of Evidence: B)
4. In patients referred for CABG, short-acting intravenous GP
IIb/IIIa inhibitors (eptiﬁbatide or tiroﬁban) should be dis-
continued for at least 2 to 4 hours before surgery (236,237)
and abciximab for at least 12 hours before to limit blood loss
and transfusion (238). (Level of Evidence: B)
CLASS IIb
1. In patients referred for urgent CABG, it may be reasonable to
perform surgery less than 5 days after clopidogrel or tica-
grelor has been discontinued and less than 7 days after
prasugrel has been discontinued. (Level of Evidence: C)
6. LATE HOSPITAL CARE, HOSPITAL DISCHARGE,
AND POSTHOSPITAL DISCHARGE CARE:
RECOMMENDATIONS
6.1. Medical Regimen and Use of Medications at Discharge
CLASS I
1. Medications required in the hospital to control ischemia
should be continued after hospital discharge in patients with
NSTE-ACS who do not undergo coronary revascularization,
patients with incomplete or unsuccessful revascularization,
and patients with recurrent symptoms after revasculariza-
tion. Titration of the doses may be required (239,240).
(Level of Evidence: C)
2. All patients who are postNSTE-ACS should be given
sublingual or spray nitroglycerin with verbal and written
instructions for its use (241). (Level of Evidence: C)
3. Before hospital discharge, patients with NSTE-ACS should
be informed about symptoms of worsening myocardial
ischemia and MI and should be given verbal and written in-
structions about how and when to seek emergency care for
such symptoms (241). (Level of Evidence: C)
4. Before hospital discharge, patients who are postNSTE-ACS
and/or designated responsible caregivers should be pro-
vided with easily understood and culturally sensitive verbal
and written instructions about medication type, purpose,
dose, frequency, side effects, and duration of use (241).
(Level of Evidence: C)
5. For patients who are postNSTE-ACS and have initial angina
lasting more than 1 minute, nitroglycerin (1 dose sublingual
or spray) is recommended if angina does not subside within 3
to 5 minutes; call 9-1-1 immediately to access emergency
medical services (241). (Level of Evidence: C)
6. If the pattern or severity of angina changes, suggesting
worsening myocardial ischemia (e.g., pain is more frequent
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patients should contact their clinician without delay to
assess the need for additional treatment or testing (241).
(Level of Evidence: C)
7. Before discharge, patients should be educated about modi-
ﬁcation of cardiovascular risk factors (240). (Level of
Evidence: C)
6.2. Late Hospital and Posthospital Oral Antiplatelet Therapy
CLASS I
1. Aspirin should be continued indeﬁnitely. The maintenance
dose should be 81 mg daily in patients treated with tica-
grelor and 81 mg to 325 mg daily in all other patients
(142–144). (Level of Evidence: A)
2. In addition to aspirin, a P2Y12 inhibitor (either clopidogrel or
ticagrelor) should be continued for up to 12 months in all
patients with NSTE-ACS without contraindications who are
treated with an ischemia-guided strategy. Options include:
 Clopidogrel: 75 mg daily (143,171) (Level of Evidence: B) or
 Ticagrelork: 90 mg twice daily (147,148) (Level of
Evidence: B)
3. In patients receiving a stent (bare-metal stent or DES) during
PCI for NSTE-ACS, P2Y12 inhibitor therapy should be given
for at least 12 months (169). Options include:
 Clopidogrel: 75 mg daily (170,171) (Level of Evidence: B) or
 Prasugrel#: 10 mg daily (172) (Level of Evidence: B) or
 Ticagrelork: 90 mg twice daily (147) (Level of Evidence: B)
CLASS IIa
1. It is reasonable to use an aspirin maintenance dose of 81 mg per
day in preference to higher maintenance doses in patients with
NSTE-ACS treated either invasively or with coronary stent im-
plantation (27,170,190,209–212). (Level of Evidence: B)
2. It is reasonable to use ticagrelor in preference to clopidogrel
for maintenance P2Y12 treatment in patients with NSTE-ACS
who undergo an early invasive or ischemia-guided strategy
(147,148). (Level of Evidence: B)
3. It is reasonable to choose prasugrel over clopidogrel for
maintenance P2Y12 treatment in patients with NSTE-ACS
who undergo PCI who are not at high risk for bleeding
complications (172,205). (Level of Evidence: B)
4. If the risk of morbidity from bleeding outweighs the antici-
pated beneﬁt of a recommended duration of P2Y12 inhibitor
therapy after stent implantation, earlier discontinuation
(e.g., <12 months) of P2Y12 inhibitor therapy is reasonable
(169). (Level of Evidence: C)#Patients should receive a loading dose of prasugrel provided that they were
not pretreated with another P2Y12 receptor inhibitor.
kThe recommended maintenance dose of aspirin to be used with ticagrelor is
81 mg daily (144).CLASS IIb
1. Continuation of DAPT beyond 12 months may be con-
sidered in patients undergoing stent implantation. (Level of
Evidence: C)6.3. Combined Oral Anticoagulant Therapy and
Antiplatelet Therapy in Patients With NSTE-ACS
CLASS I
1. The duration of triple antithrombotic therapy with a
vitamin K antagonist, aspirin, and a P2Y12 receptor inhibi-
tor in patients with NSTE-ACS should be minimized to the
extent possible to limit the risk of bleeding. (Level of
Evidence: C)
2. Proton pump inhibitors should be prescribed in patients
with NSTE-ACS with a history of gastrointestinal bleeding
who require triple antithrombotic therapy with a vitamin K
antagonist, aspirin, and a P2Y12 receptor inhibitor
(27,242,243). (Level of Evidence: C)
CLASS IIa
1. Proton pump inhibitor use is reasonable in patients with
NSTE-ACS without a known history of gastrointestinal
bleeding who require triple antithrombotic therapy with a
vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor
(27,242,243). (Level of Evidence: C)
CLASS IIb
1. Targeting oral anticoagulant therapy to a lower international
normalized ratio (e.g., 2.0 to 2.5) may be reasonable in
patients with NSTE-ACS managed with aspirin and a P2Y12
inhibitor. (Level of Evidence: C)6.4. Risk Reduction Strategies for Secondary Prevention
CLASS I
1. All eligible patients with NSTE-ACS should be referred to a
comprehensive cardiovascular rehabilitation program either
before hospital discharge or during the ﬁrst outpatient visit
(244–247). (Level of Evidence: B)
2. The pneumococcal vaccine is recommended for patients
65 years of age and older and in high-risk patients with
cardiovascular disease (248–250). (Level of Evidence: B)
3. Patients should be educated about appropriate cholesterol
management, blood pressure (BP), smoking cessation, and
lifestyle management (16,17,19). (Level of Evidence: C)
4. Patients who have undergone PCI or CABG derive beneﬁt
from risk factor modiﬁcation and should receive counseling
that revascularization does not obviate the need for lifestyle
changes (251). (Level of Evidence: C)
5. Before hospital discharge, the patient’s need for treatment
of chronic musculoskeletal discomfort should be assessed,
and a stepped-care approach should be used for selection
of treatments. Pain treatment before consideration of NSAIDs
**Those $75 years of age (see Section 7.1 in the full-text CPG).
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tramadol, or small doses of narcotics if these medications
are not adequate (18,252). (Level of Evidence: C)
CLASS IIa
1. It is reasonable to use nonselective NSAIDs, such as nap-
roxen, if initial therapy with acetaminophen, nonacetylated
salicylates, tramadol, or small doses of narcotics is insufﬁ-
cient (252). (Level of Evidence: C)
CLASS IIb
1. NSAIDs with increasing degrees of relative cyclooxygenase-2
selectivity may be considered for pain relief only for situa-
tions in which intolerable discomfort persists despite
attempts at stepped-care therapy with acetaminophen,
nonacetylated salicylates, tramadol, small doses of nar-
cotics, or nonselective NSAIDs. In all cases, use of the lowest
effective doses for the shortest possible time is encouraged
(117,118,252,253). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Antioxidant vitamin supplements (e.g., vitamins E, C,
or beta carotene) should not be used for secondary pre-
vention in patients with NSTE-ACS (254,255). (Level of
Evidence: A)
2. Folic acid, with or without vitamins B6 and B12, should not be
used for secondary prevention in patients with NSTE-ACS
(256,257). (Level of Evidence: A)
CLASS III: HARM
1. Hormone therapy with estrogen plus progestin, or estrogen
alone, should not be given as new drugs for secondary
prevention of coronary events to postmenopausal women
after NSTE-ACS and should not be continued in previous
users unless the beneﬁts outweigh the estimated risks
(18,258–260). (Level of Evidence: A)
2. NSAIDs with increasing degrees of relative cyclooxygenase-2
selectivity should not be administered to patients with
NSTE-ACS and chronic musculoskeletal discomfort when
therapy with acetaminophen, nonacetylated salicylates,
tramadol, small doses of narcotics, or nonselective NSAIDs
provide acceptable pain relief (117,118,252,253). (Level of
Evidence: B)
6.5. Plan of Care for Patients With NSTE-ACS
CLASS I
1. Posthospital systems of care designed to prevent hospital
readmissions should be used to facilitate the transition to
effective, coordinated outpatient care for all patients with
NSTE-ACS (261–265). (Level of Evidence: B)
2. An evidence-based plan of care (e.g., GDMT) that promotes
medication adherence, timely follow-up with the healthcare
team, appropriate dietary and physical activities, and
compliance with interventions for secondary preventionshould be provided to patients with NSTE-ACS. (Level of
Evidence: C)
3. In addition to detailed instructions for daily exercise, patients
should be given speciﬁc instruction on activities (e.g., lifting,
climbing stairs, yard work, and household activities) that
are permissible and those to avoid. Speciﬁc mention should
be made of resumption of driving, return to work, and sexual
activity (247,266,267). (Level of Evidence: B)
4. An annual inﬂuenza vaccination is recommended for
patients with cardiovascular disease (28,268). (Level of
Evidence: C)
7. SPECIAL PATIENT GROUPS: RECOMMENDATIONS
See Table 10 for summary of recommendations for this
section.
7.1. NSTE-ACS in Older Patients
CLASS I
1. Older patients** with NSTE-ACS should be treated with
GDMT, an early invasive strategy, and revascularization as
appropriate (269–273). (Level of Evidence: A)
2. Pharmacotherapy in older patients** with NSTE-ACS should
be individualized and dose adjusted by weight and/or CrCl
to reduce adverse events caused by age-related changes
in pharmacokinetics/dynamics, volume of distribution,
comorbidities, drug interactions, and increased drug sensi-
tivity (269,274–276). (Level of Evidence: A)
3. Management decisions for older patients** with NSTE-ACS
should be patient centered, considering patient prefer-
ences/goals, comorbidities, functional and cognitive status,
and life expectancy (269,277–279). (Level of Evidence: B)
CLASS IIa
1. Bivalirudin, rather than a GP IIb/IIIa inhibitor plus UFH, is
reasonable in older patients** with NSTE-ACS, both initially
and at PCI, given similar efﬁcacy but less bleeding risk
(215,280–282). (Level of Evidence: B)
2. It is reasonable to choose CABG over PCI in older patients**
with NSTE-ACS who are appropriate candidates, particularly
those with diabetes mellitus or complex 3-vessel CAD (e.g.,
SYNTAX score >22), with or without involvement of the
proximal left anterior descending artery, to reduce cardio-
vascular disease events and readmission and to improve
survival (283–288). (Level of Evidence: B)
7.2. Heart Failure and Cardiogenic Shock
CLASS I
1. Patients with a history of HF and NSTE-ACS should be tre-
ated according to the same risk stratiﬁcation guidelines and
recommendations for patients without HF (15,40–42,52–58).
(Level of Evidence: B)
TABLE 10 Summary of Recommendations for Special Patient Groups
Recommendations COR LOE References
NSTE-ACS in older patients
Treat older patients ($75 y of age) with GDMT, early invasive strategy, and revascularization
as appropriate
I A (269–273)
Individualize pharmacotherapy in older patients, with dose adjusted by weight and/or CrCl
to reduce adverse events caused by age-related changes in pharmacokinetics/dynamics,
volume of distribution, comorbidity, drug interactions, and increased drug sensitivity
I A (269,274–276)
Undertake patient-centered management for older patients, considering patient preferences/
goals, comorbidities, functional and cognitive status, and life expectancy
I B (269,277–279)
Bivalirudin rather than GP IIb/IIIa inhibitor plus UFH is reasonable for older patients
($75 y of age), given similar efﬁcacy but less bleeding risk
IIa B (215,280–282)
It is reasonable to choose CABG over PCI in older patients, particularly those with DM or
multivessel disease, because of the potential for improved survival and reduced CVD events
IIa B (283–288)
HF and cardiogenic shock
Treat patients with a history of HF according to the same risk stratiﬁcation guidelines and
recommendations for patients without HF
I B (15,40–42,52–58)
Select a revascularization strategy based on the extent of CAD, associated cardiac lesions,
LV dysfunction, and prior revascularization
I B (15,173,175,177,178,289–292)
Recommend early revascularization for cardiogenic shock due to cardiac pump failure I B (291,293,294)
DM
Recommend medical treatment and decisions for testing and revascularization similar to
those for patients without DM
I A (173,176,295)
Post–CABG
Recommend GDMT antiplatelet and anticoagulant therapy and early invasive strategy
because of increased risk with prior CABG
I B (44,45,178,290,296,297)
Perioperative NSTE-ACS
Administer GDMT to perioperative patients with limitations imposed by noncardiac surgery I C (298,299)
Direct management at underlying cause of perioperative NSTE-ACS I C (22,298–306)
CKD
Estimate CrCl and adjust doses of renally cleared medications according to
pharmacokinetic data
I B (307,308)
Administer adequate hydration to patients undergoing coronary and LV angiography I C N/A
Invasive strategy is reasonable in patients with mild (stage 2) and moderate (stage 3) CKD IIa B (307–310)
Women
Manage women with the same pharmacological therapy as that for men for acute care
and secondary prevention, with attention to weight and/or renally calculated doses
of antiplatelet and anticoagulant agents to reduce bleeding risk
I B (311–315)
Early invasive strategy is recommended in women with NSTE-ACS and high-risk features
(troponin positive)
I A (178,292,316,317)
Myocardial revascularization is reasonable for pregnant women if ischemia-guided strategy
is ineffective for management of life-threatening complications
IIa C (318)
Women with low-risk features (Section 3.3.1 in the full-text CPG) should not undergo
early invasive treatment because of lack of beneﬁt and the possibility of harm
III: No Beneﬁt B (178,316,317)
Anemia, bleeding, and transfusion
Evaluate all patients for risk of bleeding I C N/A
Recommend that anticoagulant and antiplatelet therapy be weight-based where
appropriate and adjusted for CKD to decrease the risk of bleeding
I B (276,319,320)
There is no beneﬁt of routine blood transfusion in hemodynamically stable patients
with hemoglobin levels >8 g/dL
III: No Beneﬁt B (321–325)
Continued on the next page
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TABLE 10 Continued
Recommendations COR LOE References
Cocaine and methamphetamine users
Manage patients with recent cocaine or methamphetamine use similarly to those
without cocaine- or methamphetamine-related NSTE-ACS. The exception is
in patients with signs of acute intoxication (e.g., euphoria, tachycardia, and
hypertension) and beta-blocker use unless patients are receiving coronary
vasodilator therapy
I C N/A
It is reasonable to use benzodiazepines alone or in combination with NTG
to manage hypertension and tachycardia and signs of acute cocaine or
methamphetamine intoxication
IIa C (326–329)
Do not administer beta blockers to patients with recent cocaine or
methamphetamine use who have signs of acute intoxication due
to risk of potentiating coronary spasm
III: Harm C N/A
Vasospastic (Prinzmetal) angina
Recommend CCBs alone or in combination with nitrates I B (330–335)
Recommend HMG-CoA reductase inhibitor, cessation of tobacco use, and
atherosclerosis risk factor modiﬁcation
I B (336–340)
Recommend coronary angiography (invasive or noninvasive) for episodic chest
pain with transient ST-elevation to detect severe CAD
I C N/A
Provocative testing during invasive coronary angiography* may be considered
for suspected vasospastic angina when clinical criteria and noninvasive
assessment fail to determine diagnosis
IIb B (341–344)
ACS with angiographically normal coronary arteries
Invasive physiological assessment (coronary ﬂow reserve measurement)
may be considered with normal coronary arteries if endothelial
dysfunction is suspected
IIb B (301,345–348)
Stress (Takotsubo) cardiomyopathy
Consider stress-induced cardiomyopathy in patients with apparent ACS
and nonobstructive CAD
I C N/A
Perform ventriculography, echocardiography, or MRI to conﬁrm or
exclude diagnosis
I B (349–352)
Treat with conventional agents (ACE inhibitors, beta blockers, aspirin,
and diuretics) if hemodynamically stable
I C N/A
Administer anticoagulant therapy for LV thrombi I C N/A
It is reasonable to administer catecholamines for symptomatic hypotension
in the absence of LV outﬂow tract obstruction
IIa C N/A
It is reasonable to use IABP for refractory shock IIa C N/A
It is reasonable to use beta blockers and alpha-adrenergic agents for LV
outﬂow tract obstruction
IIa C N/A
Prophylactic anticoagulation may be considered to prevent LV thrombi IIb C N/A
*Provocative testing during invasive coronary angiography (e.g., using ergonovine, acetylcholine, methylergonovine) is relatively safe, especially when performed in a controlled
manner by experienced operators. However, sustained spasm, serious arrhythmias, and even death can also occur but very infrequently. Therefore, provocative tests should be avoided
in patients with signiﬁcant left main disease, advanced 3-vessel disease, presence of high-grade obstructive lesions, signiﬁcant valvular stenosis, signiﬁcant LV systolic dysfunction,
and advanced HF.
ACE indicates angiotensin-converting enzyme; ACS, acute coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CKD,
chronic kidney disease; COR, Class of Recommendation; CPG, clinical practice guideline; CrCl, creatinine clearance; CVD, cardiovascular disease; DM, diabetes mellitus; GDMT,
guideline-directed medical therapy; GP, glycoprotein; HF, heart failure; IABP, intra-aortic balloon pump; LOE, Level of Evidence; LV, left ventricular; MRI, magnetic resonance imaging;
N/A, not available; NSTE-ACS, non–ST-elevation acute coronary syndrome; NTG, nitroglycerin; PCI, percutaneous coronary intervention; and UFH, unfractionated heparin.
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be based on the degree, severity, and extent of CAD;
associated cardiac lesions; the extent of LV dysfunction;
and the history of prior revascularization procedures
(15,173,175,177,178,289–292). (Level of Evidence: B)
3. Early revascularization is recommended in suitable patients
with cardiogenic shock due to cardiac pump failure after
NSTE-ACS (291,293,294). (Level of Evidence: B)7.3. Diabetes Mellitus
CLASS I
1. Medical treatment in the acute phase of NSTE-ACS and
decisions to perform stress testing, angiography, and
revascularization should be similar in patients with
and without diabetes mellitus (173,176,295). (Level of
Evidence: A)
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CLASS I
1. Patients with prior CABG and NSTE-ACS should receive an-
tiplatelet and anticoagulant therapy according to GDMT and
should be strongly considered for early invasive strategy
because of their increased risk (44,45,178,290,296,297).
(Level of Evidence: B)
7.5. Perioperative NSTE-ACS Related to Noncardiac Surgery
CLASS I
1. Patients who develop NSTE-ACS following noncardiac sur-
gery should receive GDMT as recommended for patients in
the general population but with the modiﬁcations imposed
by the speciﬁc noncardiac surgical procedure and the
severity of NSTE-ACS (298,299). (Level of Evidence: C)
2. In patients who develop NSTE-ACS after noncardiac surgery,
management should be directed at the underlying cause
(22,298–306). (Level of Evidence: C)
7.6. Chronic Kidney Disease
CLASS I
1. CrCl should be estimated in patients with NSTE-ACS, and
doses of renally cleared medications should be adjusted
according to the pharmacokinetic data for speciﬁc medica-
tions (307,308). (Level of Evidence: B)
2. Patients undergoing coronary and LV angiography should
receive adequate hydration. (Level of Evidence: C)
CLASS IIa
1. An invasive strategy is reasonable in patients with mild (stage 2)
and moderate (stage 3) CKD (307–310). (Level of Evidence: B)
7.7. Women
CLASS I
1. Women with NSTE-ACS should be managed with the
same pharmacological therapy as that for men for acute care
and for secondary prevention, with attention to weight
and/or renally-calculated doses of antiplatelet and antico-
agulant agents to reduce bleeding risk (311–315). (Level of
Evidence: B)
2. Women with NSTE-ACS and high-risk features (e.g., troponin
positive) should undergo an early invasive strategy
(178,292,316,317). (Level of Evidence: A)
CLASS IIa
1. Myocardial revascularization is reasonable in pregnant
women with NSTE-ACS if an ischemia-guided strategy is
ineffective for management of life-threatening complica-
tions (318). (Level of Evidence: C)
CLASS III: NO BENEFIT
1. Women with NSTE-ACS and low-risk features (see Section
3.3.1 in the full-text CPG) should not undergo early invasivetreatment because of the lack of beneﬁt (178,316,317) and
the possibility of harm (178). (Level of Evidence: B)
7.8. Anemia, Bleeding, and Transfusion
CLASS I
1. All patients with NSTE-ACS should be evaluated for the risk
of bleeding. (Level of Evidence: C)
2. Anticoagulant and antiplatelet therapy should be weight-
based where appropriate and should be adjusted when
necessary for CKD to decrease the risk of bleeding in patients
with NSTE-ACS (276,319,320). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. A strategy of routine blood transfusion in hemodynamically
stable patients with NSTE-ACS and hemoglobin levels greater
than 8 g/dL is not recommended (321–325). (Level of Evidence: B)
7.9. Cocaine and Methamphetamine Users
CLASS I
1. Patients with NSTE-ACS and a recent history of cocaine
or methamphetamine use should be treated in the same
manner as patients without cocaine- or methamphetamine-
related NSTE-ACS. The only exception is in patients with
signs of acute intoxication (e.g., euphoria, tachycardia, and/
or hypertension) and beta-blocker use, unless patients are
receiving coronary vasodilator therapy. (Level of Evidence: C)
CLASS IIa
1. Benzodiazepines alone or in combination with nitroglyc-
erin are reasonable for management of hypertension and
tachycardia in patients with NSTE-ACS and signs of acute
cocaine or methamphetamine intoxication (326–329). (Level of
Evidence: C)
CLASS III: HARM
1. Beta blockers should not be administered to patients with
ACS with a recent history of cocaine or methamphetamine
use who demonstrate signs of acute intoxication due
to the risk of potentiating coronary spasm. (Level of
Evidence: C)
7.10. Vasospastic (Prinzmetal) Angina
CLASS I
1. CCBs alone (330–334) or in combination with long-acting
nitrates (332,335) are useful to treat and reduce the fre-
quency of vasospastic angina. (Level of Evidence: B)
2. Treatment with HMG-CoA reductase inhibitor (336,337),
cessation of tobacco use (338,339), and additional athero-
sclerosis risk factor modiﬁcation (339,340) are useful in
patients with vasospastic angina. (Level of Evidence: B)
3. Coronary angiography (invasive or noninvasive) is recom-
mended in patients with episodic chest pain accompanied by
transient ST-elevation to rule out severe obstructive CAD.
(Level of Evidence: C)
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1. Provocative testing during invasive coronary angiographyyy
may be considered in patients with suspected vasospastic
angina when clinical criteria and noninvasive testing fail to
establish the diagnosis (341–344). (Level of Evidence: B)7.11. ACS With Angiographically Normal Coronary Arteries
CLASS IIb
1. If coronary angiography reveals normal coronary arteries
and endothelial dysfunction is suspected, invasive phy-
siological assessment such as coronary ﬂow reserve
measurement may be considered (301,345–348). (Level of
Evidence: B)7.12. Stress (Takotsubo) Cardiomyopathy
CLASS I
1. Stress (Takotsubo) cardiomyopathy should be considered in
patients who present with apparent ACS and nonobstructive
CAD at angiography. (Level of Evidence: C)
2. Imaging with ventriculography, echocardiography, or mag-
netic resonance imaging should be performed to conﬁrm or
exclude the diagnosis of stress (Takotsubo) cardiomyopathy
(349–352). (Level of Evidence: B)
3. Patients should be treated with conventional agents (ACE
inhibitors, beta blockers, aspirin, and diuretics) as otherwise
indicated if hemodynamically stable. (Level of Evidence: C)
4. Anticoagulation should be administered in patients who
develop LV thrombi. (Level of Evidence: C)
CLASS IIa
1. It is reasonable to use catecholamines for patients with
symptomatic hypotension if outﬂow tract obstruction is not
present. (Level of Evidence: C)
2. The use of an intra-aortic balloon pump is reasonable for
patients with refractory shock. (Level of Evidence: C)
3. It is reasonable to use beta blockers and alpha-adrenergic
agents in patients with outﬂow tract obstruction. (Level of
Evidence: C)
CLASS IIb
1. Prophylactic anticoagulation may be considered to inhibit
the development of LV thrombi. (Level of Evidence: C)yyProvocative testing during invasive coronary angiography (e.g., using ergo-
novine, acetylcholine, methylergonovine) is relatively safe, especially when
performed in a controlled manner by experienced operators. However, sus-
tained spasm, serious arrhythmias, and even death can also occur very infre-
quently. Therefore, provocative testing should be avoided in patients with
signiﬁcant left main disease, advanced 3-vessel disease, presence of high-grade
obstructive lesions, signiﬁcant valvular stenosis, signiﬁcant LV systolic
dysfunction, and advanced HF.8. QUALITY OF CARE AND OUTCOMES FOR ACS—
USE OF PERFORMANCE MEASURES AND
REGISTRIES: RECOMMENDATION
CLASS IIa
1. Participation in a standardized quality-of-care data registry
designed to track and measure outcomes, complications, and
performance measures can be beneﬁcial in improving the
quality of NSTE-ACS care (353–361). (Level of Evidence: B)9. SUMMARY AND EVIDENCE GAPS
Despite landmark advances in the care of patients with
NSTE-ACS since the publication of the 2007 UA/NSTEMI
CPG (362), many emerging diagnostic and therapeutic
strategies have posed new challenges. There is general
acceptance of an early invasive strategy for patients with
NSTE-ACS in whom signiﬁcant coronary vascular obstruc-
tion has been precisely quantiﬁed. Low-risk patients with
NSTE-ACS are documented to beneﬁt substantially from
GDMT, but this is often suboptimally used. Advances
in noninvasive testing have the potential to identify
patients with NSTE-ACS who are at intermediate risk and
are candidates for invasive versus medical therapy.
Newer, more potent antiplatelet agents in addition to
anticoagulant therapy are indicated irrespective of initial
treatment strategy. Evidence-based decisions will require
comparative-effectiveness studies of available and novel
agents. The paradox of newer and more potent antith-
rombotic and anticoagulant drugs that reduce major
adverse cardiac outcomes but increase bleeding risk
occurs with greater frequency in patients with atrial
ﬁbrillation. Patients with atrial ﬁbrillation who develop
NSTE-ACS and receive a coronary stent are the population
at risk from triple anticoagulant/antiplatelet therapy.
This regimen has been reported to be safely modiﬁed
by elimination of aspirin, a ﬁnding that requires
conﬁrmation.
Among the most rapidly evolving areas in NSTE-ACS
diagnosis is the use of cardiac troponin, the preferred
biomarker of myocardial necrosis. Although a truly high-
sensitivity cardiac troponin is not available in the
United States at the time this CPG was prepared, the
sensitivity of contemporary assays continues to increase.
This change is accompanied by higher rates of elevated
cardiac troponin unrelated to coronary plaque rupture.
The diagnostic quandary posed by these ﬁndings neces-
sitates investigation to elucidate the optimal utility of this
advanced biomarker. A promising approach to improve
the diagnostic accuracy for detecting myocardial necrosis
is measurement of absolute cardiac troponin change,
which may be more accurate than the traditional analysis
of relative alterations.
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2670Special populations are addressed in this CPG, the most
numerous of which are older persons and women. More
than half of the mortality in NSTE-ACS occurs in older
patients, and this high-risk cohort will increase as our
population ages. An unmet need is to more clearly
distinguish which older patients are candidates for an
ischemia-guided strategy compared with an early inva-
sive management strategy. An appreciable number of
patients with NSTE-ACS have angiographically normal or
nonobstructive CAD, a group in which women predomi-
nate. Their prognosis is not benign and the multiple
mechanisms of ACS postulated for these patients remain
largely speculative. Clinical advances are predicated on
clariﬁcation of the pathophysiology of this challenging
syndrome.
A fundamental aspect of all CPGs is that these carefully
developed, evidence-based documents cannot encompass
all clinical circumstances, nor can they replace the judg-
ment of individual physicians in management of each
patient. The science of medicine is rooted in evidence,
and the art of medicine is based on the application of this
evidence to the individual patient. This CPG has adhered
to these principles for optimal management of patients
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